
==== Front
J Health Econ Outcomes Res
J Health Econ Outcomes Res
1694
Journal of Health Economics and Outcomes Research
2326-697X
2327-2236
Columbia Data Analytics, LLC Website: Journal of Health Economics and Outcomes Research

36852155
57651
10.36469/001c.57651
Nephrologic/Hepatologic Conditions
Outcomes, Healthcare Resource Utilization, and Costs of Overall, Community-Acquired, and Hospital-Acquired Acute Kidney Injury in COVID-19 Patients
https://orcid.org/0000-0001-6873-8712
Koyner Jay L. 1
https://orcid.org/0000-0001-6088-2664
Mackey Rachel H. 2 3
https://orcid.org/0000-0002-3404-3717
Rosenthal Ning A. 2
Carabuena Leslie A. 2
Kampf J. Patrick 4
McPherson Paul 4
Rodriguez Toni 5
Sanghani Aarti 6
https://orcid.org/0000-0002-3821-9337
Textoris Julien 7 8
1 Section of Nephrology University of Chicago, Chicago, Illinois
2 Premier, Inc., PINC AI Applied Sciences, Charlotte, North Carolina
3 Department of Epidemiology University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania
4 Astute Medical Inc. (a bioMerieux company), San Diego, California
5 Global Medical Affairs bioMerieux, Inc., Durham, North Carolina
6 bioMerieux, Inc., Global Medical Affairs, Durham, North Carolina
7 bioMerieux, SA, Global Medical Affairs, Lyons, France
8 Service d´Anesthésie et de Réanimation, Lyons, France
J.L.K. and R.H.M. contributed equally to this manuscript.

J.L.K. and R.H.M. contributed equally to this manuscript. Corresponding author: Email: Rachel_Mackey@premierinc.com
23 2 2023
2023
10 1 3140
14 12 2022
15 12 2022
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Background: In hospitalized patients with COVID-19, acute kidney injury (AKI) is associated with higher mortality, but data are lacking on healthcare resource utilization (HRU) and costs related to AKI, community-acquired AKI (CA-AKI), and hospital-acquired AKI (HA-AKI). Objectives: To quantify the burden of AKI, CA-AKI, and HA-AKI among inpatients with COVID-19. Methods: This retrospective cohort study included inpatients with COVID-19 discharged from US hospitals in the Premier PINC AI™ Healthcare Database April 1–October 31, 2020, categorized as AKI, CA-AKI, HA-AKI, or no AKI by ICD-10-CM diagnosis codes. Outcomes were assessed during index (initial) hospitalization and 30 days postdischarge. Results: Among 208 583 COVID-19 inpatients, 30%, 25%, and 5% had AKI, CA-AKI, and HA-AKI, of whom 10%, 7%, and 23% received dialysis, respectively. Excess mortality, HRU, and costs were greater for HA-AKI than CA-AKI. In adjusted models, for patients with AKI vs no AKI and HA-AKI vs CA-AKI, odds ratios (ORs) (95% CI) were 3.70 (3.61-3.79) and 4.11 (3.92-4.31) for intensive care unit use and 3.52 (3.41-3.63) and 2.64 (2.52-2.78) for in-hospital mortality; mean length of stay (LOS) differences and LOS ratios (95% CI) were 1.8 days and 1.24 (1.23-1.25) and 5.1 days and 1.57 (1.54-1.59); and mean cost differences and cost ratios were 7163and1.35(1.34−1.36)and19 127 and 1.78 (1.75-1.81) (all P < .001). During the 30 days postdischarge, readmission LOS was ≥6% longer for AKI vs no AKI and HA-AKI vs CA-AKI; outpatient costs were ≥41% higher for HA-AKI vs CA-AKI or no AKI. Only 30-day new dialysis (among patients without index hospitalization dialysis) had similar odds for HA-AKI vs CA-AKI (2.37-2.8 times higher for AKI, HA-AKI, or CA-AKI vs no AKI). Discussion: Among inpatients with COVID-19, HA-AKI had higher excess mortality, HRU, and costs than CA-AKI. Other studies suggest that interventions to prevent HA-AKI could decrease excess morbidity, HRU, and costs among inpatients with COVID-19. Conclusions: In adjusted models among COVID-19 inpatients, AKI, especially HA-AKI, was associated with significantly higher mortality, HRU, and costs during index admission, and higher dialysis and longer readmission LOS during the 30 days postdischarge. These findings support implementation of interventions to prevent HA-AKI in COVID-19 patients.

COVID-19
acute kidney injury (AKI)
hospital-acquired AKI
community-acquired AKI
healthcare resource utilization
costs
clinical outcomes
This work was supported by funding from bioMerieux, Inc. Design and conduct of the study, drafting of the manuscript, and decision to submit for publication was led by Premier coauthors, with collaboration from the entire study team including investigators from bioMerieux, Inc. and the University of Chicago.
==== Body
pmcBACKGROUND

Acute kidney injury (AKI) is an abrupt decrease in kidney function, defined and staged for severity based on decreased urine output and increases in serum creatinine relative to reference (baseline) creatinine levels for each patient.1 Prior to the COVID-19 pandemic, AKI occurred in 5% to 18% of adult hospitalized patients2,3 and 20% to 75% of those admitted to intensive care units (ICUs).4–7 Hospitalized patients with AKI have worse clinical outcomes,3,5,7,8 higher healthcare resource utilization (HRU),3,9 and approximately twofold higher costs than patients without AKI.3,10

AKI is now known to be a common complication of COVID-19, but it is unclear whether COVID-19 affects the kidneys directly, or indirectly, by causing more severe illness, similar to other severe infections.11 AKI may be more frequent and more severe (ie, more stage 3 AKI) in hospitalized patients with than without COVID-19, and is associated with 7 to 15 times higher mortality risk vs COVID-19 patients without AKI.12–15 Furthermore, in patients without COVID-19, AKI that first occurs in the hospital (hospital-acquired AKI [HA-AKI]) is associated with higher mortality,16 longer hospital length of stay (LOS), and higher costs17 than community-acquired AKI (CA-AKI), which occurs prior to hospital admission. However, in the few small studies among COVID-19 patients, results are mixed regarding whether mortality is increased for patients with HA-AKI vs CA-AKI.18–22 Finally, to date, no studies have evaluated costs of AKI, CA-AKI, or HA-AKI in patients with COVID-19.

Quantifying the excess burden of AKI, especially HA-AKI, could provide motivation for targeted interventions to prevent and manage AKI in COVID-19 inpatients.23 Several studies have evaluated the implementation of the Kidney Disease: Improving Global Outcomes (KDIGO) “bundle” of guideline-recommended renal-protective measures to treat and prevent AKI, including optimization of volume status and hemodynamics, functional hemodynamic monitoring, avoidance of nephrotoxic drugs, and prevention of hyperglycemia.1 In non-COVID-19 patients, early identification and use of the KDIGO bundle can reduce the incidence,24–26 severity,27 duration,28 and progression of AKI29 and hospital LOS27,28 and costs.30,31 For example, the Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) study found that the cost of an AKI alert and outreach intervention was lower than usual care.31 Also, the UK-based Tackling AKI study demonstrated that implementation of a multifaceted AKI intervention (e-alerts, care bundle, and an education program) resulted in shorter hospital LOS28 and lower costs for AKI patients.30 However, adherence to best practices (the KDIGO bundle) remains low among patients at high risk of AKI.26,32,33 Therefore, the objective of the current study was to evaluate the prevalence and incidence of AKI, CA-AKI, and HA-AKI and quantify associated clinical outcomes, healthcare resource utilization (HRU), and costs among adults hospitalized with COVID-19, to provide data to motivate improved prevention and management of AKI in COVID-19 patients.

METHODS

Data Source, Study Timeline, Cohort, and Exposure

We included patients with a COVID-19 discharge diagnosis from April 1, 2020, to October 31, 2020, from a US hospital in the Premier PINC AI™ Healthcare Database (PHD), formerly known as the Premier Healthcare Database, which has been widely used for published studies by the US Centers for Disease Control and Prevention and others.34–37 The PHD contains discharge information (eg, demographics, diagnosis and procedure codes, discharge status, and costs) from inpatient and hospital-based outpatient visits from more than 1000 geographically diverse hospitals and health systems. Masked identifiers track patients across inpatient and hospital-based outpatient settings within the same hospital/system. The PHD data are statistically de-identified and compliant with HIPAA (Health Insurance Portability and Accountability Act). Based on 45 CFR §46, the study was exempt from institutional review board approval, as in prior PHD studies. This study followed RECORD (REporting of studies Conducted using Observational Routinely collected health Data) guidelines, specifically for studies using administrative health data.

The first hospitalization with discharge from April 1, 2020, through October 31, 2020, that met inclusion and exclusion selection criteria (Supplemental Figure S1) was the index hospitalization. Inclusions were age 18 years and older and COVID-19 International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code U07.1. Exclusions, defined using ICD-10 diagnosis or procedure or current procedural terminology (CPT) codes (Supplemental Table S1), were renal transplantation or end-stage renal disease during index hospitalization or 365-day look-back period; more than 1 hospital inpatient or outpatient visits with dialysis-related ICD-10 diagnosis or procedure codes or CPT codes (Supplemental Table S1) during 365-day look-back period; or ICD-10 diagnosis code for stage 5 chronic kidney disease (CKD) (N18.5) with present on admission (POA) indicator = Yes.

The exposure, AKI, was defined by presence of ICD-10-CM diagnosis code N17.% during index hospitalization. AKI was subcategorized as CA-AKI, defined by POA = Yes, and HA-AKI, defined by POA = No (Supplemental Methods).

Patient, Visit, Clinical, and Hospital Characteristics

Patient, visit, and hospital characteristics were evaluated during the index hospitalization. Patient demographics included age, sex, race/ethnicity, and primary payer. Hospital characteristics included size (number of beds), geographic region, urban vs rural, and teaching status. The ICD-10-CM diagnosis codes from the index hospitalization and 365 days prior were used to identify comorbidities including CKD, hypertension, and anemia (Supplemental Table S2) and the Deyo-modified Charlson Comorbidity Index (CCI) score (Supplemental Table S3). The ICD-10-CM diagnosis codes during index hospitalization were used to define dehydration with POA = Yes (E86.0), and sepsis, and acute respiratory failure (Supplemental Table S2).

Outcomes

Primary outcomes were dialysis, in-hospital mortality, ICU admission, total LOS and costs, and ICU LOS and costs during index hospitalization, as previously described. Secondary outcomes, assessed during 30 days postdischarge (alive) from index hospitalization, were readmissions, readmission LOS and costs, outpatient visits and costs, in-hospital mortality, dialysis, and “new” dialysis, which excludes patients with dialysis during index hospitalization.

Admission to ICU was defined as the percentage of patients who had any ICU service charge during index hospitalization. Total LOS was hospital-reported LOS for the Index hospitalization. Total costs are the sum of all costs incurred during the index hospitalization. The ICU LOS was calculated as number of days with ICU room and board charges during the index hospitalization. ICU costs are calculated as the sum of all costs incurred on the days with ICU room and board charges. Cost data in the PHD are based on a micro-costing approach from a hospital perspective. The PHD uses a reconciliation process that allows for verification and validation of hospital reporting for the use of resources and cost. Data audits are performed, and if reported costs submitted do not match the hospital’s financial statement, Premier works with the hospital to correct the discrepancy.

Statistical Analysis

Characteristics, clinical outcomes, LOS, and costs were compared using descriptive statistics, with P values from the χ2 test, t test, or Wilcoxon rank-sum test, as appropriate. Adjusted models included age, sex, race/ethnicity, CCI score, hospital characteristics (number of beds, teaching status, region, urban/rural), admission point of origin, admission type, medical vs surgical (categorized by Medicare Severity Diagnosis Related Group [MS-DRG]), primary payer, CKD, and ICU use, and, in a sensitivity analysis, sepsis. For clinical outcomes, logistic regression quantified unadjusted and multivariable-adjusted odds ratios (OR) and 95% CI.

Generalized linear model (GLM) regression with a log link and negative binomial distribution was used to quantify unadjusted and adjusted LOS ratios (eg, the ratio of LOS for patients with AKI vs no AKI) with 95% CIs. Unadjusted and adjusted mean cost ratios were quantified using a GLM with a log link and gamma distribution. For LOS and cost outcomes with many zeros (eg, ICU LOS), a 2-part (ie, “hurdle”) model was used.38 In a 2-part model, first, a logistic regression model estimated the probability of having any costs (eg, any ICU use).38 Second, for patients with any use, a GLM with log link quantified relative differences in LOS and costs (ie, LOS ratio [95% CI], using a negative binomial distribution], or cost ratio [95% CI; using a gamma distribution]).

Finally, the absolute difference in adjusted mean LOS and costs was calculated using the recycled prediction method. The recycled prediction method uses the fitted regression models to predict adjusted outcome values (eg, cost or LOS) for each participant, first, as if all patients had AKI and then as if all patients did not have AKI, with all other covariates at the levels for that participant. The mean difference between the 2 exposure groups (eg, AKI vs no AKI) is the difference in adjusted mean cost or LOS is the difference between the mean predicted LOS or costs when exposure is set to the first group minus mean predicted LOS or costs when exposure is set to the second group. To obtain 95% CIs of the mean difference, random bootstrap resampling with 1000 iterations was used to create a distribution where the 2.5th and 97.5th percentiles are the 95% lower and upper bound CIs, respectively.39

RESULTS

Study Cohort

During the study period, 220 056 adult patients with a COVID-19 ICD-10 diagnosis code were discharged from 829 US hospitals. Exclusion criteria removed 11 473 patients: 9136 for end-stage renal disease and 2337 for other exclusions, leaving 208 583 patients in the study cohort (Figure 1). Overall, the prevalence of AKI and CA-AKI were 30% and 25%, and the incidence of HA-AKI was 5%. Among the 49 990 (24%) of patients with ICU use, the corresponding AKI proportions were 52.1%, 37.3%, and 14.8%, and among the 158 593 (76%) patients without ICU use were 23.0%, 21.0%, and 2.0%, respectively. However, 58.4% (36 524/62 553) of AKI cases and 29.6% (3107/10 505) of HA-AKI cases occurred among non-ICU patients.

134666 Figure 1. Patient Flow Diagram

Abbreviations: AKI, acute kidney injury; CA-AKI, community-acquired AKI; CKD, chronic kidney disease; EGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HA-AKI, hospital-acquired AKI; POA, present on admission.

Baseline Characteristics and Discharge Status

Patients with AKI, CA-AKI, and HA-AKI had higher mean age, were more likely to be men, Black, and in larger, urban, Northeast teaching hospitals; have emergency admissions, transfers from another facility (acute care or long-term), CKD, hypertension, diabetes, anemia, or higher mean CCI scores; and have dehydration POA, sepsis, or acute respiratory failure during hospitalization (Table 1, P < .005 for all vs no AKI). Patients with AKI, CA-AKI, and HA-AKI were also more likely to die or be discharged to hospice or a nursing or rehabilitation facility.

134667 Table 1. Characteristics of Patients With COVID-19, Overall and by AKI Categories, Index Hospitalization (N = 208 583)

	No AKI (n = 146 030)	AKI (n = 62 553)	CA-⁠AKI (n = 52 048)	HA-⁠AKI (n = 10 505)	
Age (y), mean ± SD	58.9 ± 18.6	69.3 ± 14.8	69.8 ± 14.9	67.1 ± 14.2	
Age group (y), n (%)	
18-39	25 839 (17.7)	2425 (3.9)	2001 (3.8)	424 (4.0)	
40-59	45 583 (31.2)	12 329 (19.7)	9888 (19.0)	2441 (23.2)	
60-74	41 982 (28.7)	22 992 (36.8)	18 716 (36.0)	4276 (40.7)	
≥75	 626 (22.3)	 807 (39.7)	 443 (41.2)	3364 (32.0)	
Gender, n (%)	
Male	69 252 (47.4)	37 252 (59.6)	30 863 (59.3)	6389 (60.8)	
Race/ethnicity, n (%)	
Non-⁠Hispanic White	67 067 (45.9)	27 862 (44.5)	23 420 (45.0)	4442 (42.3)	
Non-Hispanic Black	25 549 (17.5)	16 873 (27.0)	14 698 (28.2)	2175 (20.7)	
Hispanic	34 084 (23.3)	9637 (15.4)	7366 (14.2)	2271 (21.6)	
Other or unknown	19 330 (13.2)	8181 (13.1)	6564 (12.6)	1617 (15.4)	
Primary payer, n (%)	
Medicare	60 690 (41.6)	40 599 (64.9)	34 491 (66.3)	6108 (58.1)	
Medicaid	26 471 (18.1)	6951 (11.1)	5503 (10.6)	1448 (13.8)	
Private insurance	42 837 (29.3)	11 031 (17.6)	8785 (16.9)	2246 (21.4)	
Uninsured	6926 (4.7)	1462 (2.3)	1175 (2.3)	287 (2.7)	
Other/unknown	9106 (6.2)	2510 (4.0)	2094 (4.0)	416 (4.0)	
Hospital size, n (%)	
1-299	54 233 (37.1)	22 013 (35.2)	18 700 (35.9)	3313 (31.5)	
300-499	43 288 (29.6)	19 137 (30.6)	16 028 (30.8)	3109 (29.6)	
≥500	48 368 (33.1)	21 355 (34.1)	17 288 (33.2)	4067 (38.7)	
Population served, n (%)	
Rural	17 479 (12.0)	6542 (10.5)	5597 (10.8)	945 (9.0)	
Urban	128 551 (88.0)	56 011 (89.5)	46 451 (89.2)	9560 (91.0)	
Teaching status, n (%)	
Non-teaching	77 636 (53.2)	30 297 (48.4)	25 416 (48.8)	4881 (46.5)	
Teaching	68 394 (46.8)	32 256 (51.6)	26 632 (51.2)	5624 (53.5)	
Region of hospital, n (%)	
Midwest	27 057 (18.5)	12 162 (19.4)	10 445 (20.1)	1717 (16.3)	
Northeast	28 703 (19.7)	15 665 (25.0)	12 721 (24.4)	2944 (28.0)	
South	70 875 (48.5)	28 130 (45.0)	23 663 (45.5)	4467 (42.5)	
West	19 395 (13.3)	6596 (10.5)	5219 (10.0)	1377 (13.1)	
Admission type, n (%)	
Elective	6933 (4.7)	1092 (1.7)	917 (1.8)	175 (1.7)	
Emergency	118 975 (81.5)	54 207 (86.7)	45 214 (86.9)	8993 (85.6)	
Urgent	18 747 (12.8)	6884 (11.0)	5614 (10.8)	1270 (12.1)	
Trauma center	487 (0.3)	158 (0.3)	136 (0.3)	22 (0.2)	
Unknown	888 (0.6)	212 (0.3)	167 (0.3)	45 (0.4)	
Admission point of origin, n (%)	
Non-healthcare facility (eg, home)	119 463 (81.8)	48 729 (77.9)	40 395 (77.6)	8334 (79.3)	
Clinic	7698 (5.3)	2907 (4.6)	2505 (4.8)	402 (3.8)	
Transfer from acute care facility	13 346 (9.1)	6734 (10.8)	5424 (10.4)	1310 (12.5)	
Transfer from long-term care facility	4389 (3.0)	3737 (6.0)	3347 (6.4)	390 (3.7)	
Other/unknown	1134 (0.8)	446 (0.7)	377 (0.7)	69 (0.7)	
MS-DRG categorization, n (%)	
Medical	138 390 (94.8)	58 530 (93.6)	49 586 (95.3)	8944 (85.1)	
Surgical	7597 (5.2)	4013 (6.4)	2457 (4.7)	1556 (14.8)	
History of comorbidities, n (%)	
Charlson Comorbidity Index	1.5 ± 1.9	3.0 ± 2.4	3.1 ± 2.4	2.7 ± 2.4	
Charlson comorbidities	
Chronic kidney disease	12 413 (8.5)	26 334 (42.1)	23 249 (44.7)	3085 (29.4)	
Hypertension	85 584 (58.6)	52 341 (83.7)	43 884 (84.3)	8457 (80.5)	
Diabetes	50 941 (34.9)	33 320 (53.3)	27 710 (53.2)	5610 (53.4)	
Anemia	26 886 (18.4)	23 166 (37.0)	18 688 (35.9)	4478 (42.6)	
In-hospital complications	
Dehydration present on admission	11 822 (8.1)	14 982 (24.0)	13 929 (26.8)	1053 (10.0)	
Sepsis	30 182 (20.7)	29 559 (47.3)	22 593 (43.4)	6966 (66.3)	
Acute respiratory failure	73 521 (50.3)	36 895 (59.0)	30 664 (58.9)	6231 (59.3)	
Discharge status	
Home	91 148 (62.4)	16 927 (27.1)	15 758 (30.3)	1169 (11.1)	
Home health	16 398 (11.2)	6997 (11.2)	6120 (11.8)	877 (8.3)	
Nursing or rehabilitation facility	19 421 (13.3)	13 222 (21.1)	11 189 (21.5)	2033 (19.4)	
Transferred to an acute care hospital	696 (0.5)	262 (0.4)	229 (0.4)	33 (0.3)	
Hospice	3141 (2.2)	3175 (5.1)	2801 (5.4)	374 (3.6)	
Expired	8730 (6.0)	19 388 (31.0)	13 721 (26.4)	5667 (53.9)	
Other/unknown	6496 (4.4)	2582 (4.1)	2230 (4.3)	352 (3.4)	
For age and Charlson Comorbidity Index, results are reported as mean (SD) and compared using t test. Categorical variables are compared using χ2 test. P < .005 for all comparisons vs AKI. P < .005 for HA-AKI vs CA-AKI except diabetes (P = .76).

Abbreviations: AKI, acute kidney injury; CA-AKI, community-acquired AKI; HA-AKI, hospital-acquired AKI; MS-DRG, Medicare Severity Diagnosis Related Group.

In contrast, compared with CA-AKI, patients with HA-AKI had a slightly lower mean age (approximately 67 vs 70 years) and were less likely to be Black, have a history of CKD or hypertension, but were more likely to have a history of anemia, had a lower mean CCI, and had less dehydration POA, more sepsis, and slightly more acute respiratory failure (Table 1, P < .005 for all). Compared with CA-AKI, patients with HA-AKI were also slightly more likely to be in large, urban, teaching hospitals in the Northeast and more likely to die during index hospitalization.

Clinical Outcomes During Index Hospitalization and 30-day Follow-up

During index hospitalization, the incidence of dialysis was 9.7% in AKI, 7.0% in CA-AKI, and 23.4% in HA-AKI patients (Table 2, P < .0001 for HA-AKI vs CA-AKI). Overall, 36.4% (76 019) of patients were admitted to the ICU, but patients with AKI, CA-AKI, and HA-AKI had much higher ICU use (35.8%-70.4% vs 16.4%) and in-hospital mortality (26.4%-53.9% vs 6.0%) than patients without AKI (Table 2, P < .0001 for all). During 30-day follow-up, patients with AKI, CA-AKI, and HA-AKI also had higher rates of readmission (8.7%-10.1% vs 6.8%), in-hospital mortality (1.1%-1.6% vs 0.7%), dialysis (0.6%-0.7% vs 0.1%), and “new” dialysis (0.3%-0.4% vs 0.1%), than patients without AKI (P < .005 for all), but less outpatient visits (P < .05) (Table 2). Furthermore, compared with CA-AKI, patients with HA-AKI had substantially higher ICU use (70.4% vs 35.8%) and in-hospital mortality (53.9% vs 26.4%) (⁠P < .0001 for both), but slightly lower readmissions (8.7% vs 10.1%, P = .003) and 30-day in-hospital mortality (1.1% vs 1.6%, P = .014) and similar 30-day outpatient visits and new dialysis (Table 2).

134668 Table 2. Unadjusted Clinical Outcomes of Patients With COVID-19 by AKI Categories

	No AKI (n=146 030)	AKI
(n=62 553)	CA-AKI (n=52 048)	HA-AKI (n=10 505)	P Values	
AKI vs No AKI	HA-AKI
vs No AKI	CA-AKI
vs No AKI	HA-⁠AKI vs CA-AKI	
Outcomes during index hospitalization	
Dialysis, n (%)	84
(0.1)	6083
(9.7)	3630
(7.0)	2453
(23.4)	<.0001	<.0001	<.0001	<.0001	
ICU admission, n (%)	23 961
(16.4)	26 029
(41.6)	18 631
(35.8)	7398
(70.4)	<.0001	<.0001	<.0001	<.0001	
In-⁠hospital mortality, n (%)	8730
(6.0)	19 388
(31.0)	13 721
(26.4)	5667
(53.9)	<.0001	<.0001	<.0001	<.0001	
Outcomes during 30 days postdischarge	
Patients surviving index hospitalization	
No. at risk	137 300	43 165	38 327	4838					
30-day readmission, n (%)	9280
(6.8)	4278
(9.9)	3856
(10.1)	422
(8.7)	<.0001	<.0001	<.0001	.0033	
30-⁠day outpatient visits,
n (%)	17 118
(12.5)	4930
(11.4)	4380
(11.4)	550
(11.4)	<.0001	0.0227	<.0001	.9022	
30-day in-hospital mortality, n (%)	1023
(0.7)	668
(1.5)	613
(1.6)	55
(1.1)	<.0001	0.002	<.0001	.014	
30-day dialysis, n (%)	119
(0.1)	252
(0.6)	216
(0.6)	36
(0.7)	<.0001	<.0001	<.0001	.1204	
Patients surviving index hospitalization without dialysis							
No. at risk	137 131	41 387	37 171	4216					
30-day new dialysis, n (%)	118
(0.1)	148
(0.4)	136
(0.4)	12
(0.3)	<.0001	<.0001	<.0001	.4023	
Continuous variables compared using Wilcoxon rank sum test. Categorical variables compared using χ2 test. “New” dialysis is dialysis during 30 days postdischarge among patients who survived index hospitalization with no dialysis.

Abbreviations: AKI, acute kidney injury; CA-AKI, community-acquired AKI; HA-AKI, hospital-acquired AKI; ICU, intensive care unit.

Odds of ICU use and in-hospital mortality during index hospitalization were higher for all AKI groups vs no AKI, but also for patients with HA-AKI vs those with CA-AKI, with adjusted ORs (aORs) of 4.1 for ICU use and 2.6 for in-hospital mortality (Table 3, P ≤ .001 for all). For outcomes during 30 days postdischarge, aORs for AKI, CA-AKI, and HA-AKI vs no AKI were 4.4 to 5.3 times higher for dialysis, and 2.4 to 2.8 times higher for new dialysis (Table 3, P ≤ .002 for all). In contrast, aORs for 30-day readmissions and in-hospital mortality were similar across AKI and no-AKI groups (Table 3).

134670 Table 3. Multivariable-Adjusted Odds Ratios for Clinical Outcomes by AKI Categories Among COVID-19 Patients

	AKI vs No AKI	CA-AKI vs No AKI	HA-AKI vs No AKI	HA-AKI vs CA-AKI	
OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	OR (95% CI)	P Value	
Outcomes during index hospitalization	
ICU use (n = 49 990)	
Unadjusted	3.63 (3.55, 3.71)	<.0001	2.84 (2.78, 2.91)	<.0001	12.13 (11.61, 12.68)	<.0001	4.27 (4.08, 4.47)	<.0001	
Adjusteda	3.70 (3.61, 3.79)	<.0001	2.87 (2.80, 2.95)	<.0001	11.81 (11.28, 12.37)	<.0001	4.11 (3.92, 4.31)	<.0001	
In-hospital mortality (n = 28 118)	
Unadjusted	7.06 (6.87, 7.26)	<.0001	5.63 (5.47, 5.80)	<.0001	18.42 (17.63, 19.25)	<.0001	3.27 (3.13, 3.42)	<.0001	
Adjusteda	3.52 (3.41, 3.63)	<.0001	2.88 (2.79, 2.98)	<.0001	7.61 (7.24, 8.01)	<.0001	2.64 (2.52, 2.78)	<.0001	
Outcomes during 30 days postdischarge, among survivors of index hospitalization, n = 180 465	
30-day readmissions (n = 13 558)	
Unadjusted	1.52 (1.46, 1.58)	<.0001	1.54 (1.48, 1.61)	<.0001	1.32 (1.19, 1.46)	<.0001	0.85 (0.77, 0.95)	.0034	
Adjusteda	1.03 (0.99, 1.07)	.1581	1.04 (1.00, 1.08)	.0825	0.96 (0.86, 1.06)	.4151	0.92 (0.83, 1.03)	.1349	
30-day outpatient visits (n = 22 048)	
Unadjusted	0.91 (0.88, 0.94)	<.0001	0.91 (0.87, 0.94)	<.0001	0.90 (0.82, 0.99)	.0228	0.99 (0.90, 1.09)	.9022	
Adjusteda	0.83 (0.79, 0.86)	<.0001	0.82 (0.79, 0.85)	<.0001	0.85 (0.77, 0.94)	.0008	1.04 (0.94, 1.14)	.4775	
30-day in-hospital mortality (n = 1691)	
Unadjusted	2.09 (1.90, 2.31)	<.0001	2.17 (1.96, 2.39)	<.0001	1.53 (1.17, 2.01)	.0022	0.71 (0.54, 0.93)	.0145	
Adjusteda	1.09 (0.98, 1.21)	.1149	1.10 (0.99, 1.23)	.0697	0.93 (0.70, 1.23)	.6001	0.84 (0.63, 1.11)	.2255	
30-day dialysis (n = 371)	
Unadjusted	6.77 (5.44, 8.42)	<.0001	6.53 (5.22, 8.17)	<.0001	8.64 (5.95, 12.56)	<.0001	1.32 (0.93, 1.88)	.1215	
Adjusteda	4.46 (3.50, 5.70)	<.0001	4.37 (3.41, 5.60)	<.0001	5.28 (3.53, 7.89)	<.0001	1.21 (0.84, 1.75)	.3134	
30-day new dialysisb (n = 266)	
Unadjusted	4.17 (3.27, 5.31)	<.0001	4.27 (3.33, 5.46)	<.0001	3.32 (1.83, 6.01)	<.0001	0.78 (0.43, 1.40)	.4035	
Adjusteda	2.76 (2.11, 3.61)	<.0001	2.80 (2.13, 3.68)	<.0001	2.37 (1.28, 4.38)	.0060	0.85 (0.46, 1.54)	.5859	
Abbreviations: AKI, acute kidney injury; CA-AKI, community-acquired AKI; HA-AKI, hospital-acquired AKI; ICU, intensive care unit; OR, odds ratio.

aAdjusted for age, sex, race/ethnicity, Charlson Comorbidity Index, hospital characteristics (number of beds, teaching status, region, urban/rural), admission point of origin, admission type, medical vs surgical (categorized by Medicare Severity Diagnosis Related Group), primary payer, chronic kidney disease, and ICU use.

bNew dialysis is dialysis among patients without dialysis during index admission. Outcomes during 30-day follow-up are assessed among patients who survived index hospitalization.

HRU During Index Hospitalization and 30-Day Follow-up

During index hospitalization, unadjusted and adjusted mean LOS was longer for all AKI groups vs no AKI, but also for HA-AKI vs CA-AKI (Figure 2, P < .001). Specifically, adjusted mean LOS was 1.8, 1.0, and 5.9 days longer, and on a ratio scale, 24% (LOS ratio, 1.24), 13%, and 78% longer for patients with AKI, CA-AKI, and HA-AKI vs no AKI, but also 5.1 days (57%) longer for HA-AKI vs CA-AKI (P < .0001 for all). Among patients with any ICU use, adjusted mean ICU LOS was 3.5 (53%),2.0 (32%), and 6.8 (202%) days longer in AKI, CA-AKI, and HA-AKI patients vs no AKI but also 4.8 days (54%) longer for HA-AKI vs CA-AKI (Figure 2, P < .0001). Finally, among readmitted patients, adjusted mean readmission LOS was longer (0.4, 0.3, and 1.1 days, respectively, or 5%-16%) for AKI, CA-AKI, and HA-AKI vs no AKI (Figure 2, P ≤ .02 for all) but also 0.5 days (10%) longer for HA-AKI vs CA-AKI (P = .02).

134671 Figure 2. Mean LOS, Adjusted Mean Difference, and Adjusted LOS Ratio by AKI Categories

Abbreviations: AKI, acute kidney injury; CA-AKI, community-acquired AKI; HA-AKI, hospital-acquired AKI; ICU, intensive care unit; LOS, length of stay.

Adjusted models include these covariates: age, sex, race/ethnicity, Charlson Comorbidity Index, hospital characteristics (number of beds, teaching status, region, urban/rural), and admission point of origin, admission type, medical vs surgical (categorized by Medicare Severity Diagnosis Related Group codes), primary payer, ICU use, and chronic kidney disease.

P < .0001 for all unadjusted comparisons vs no AKI; P < .005 for all unadjusted comparisons of HA-AKI vs CA-AKI.

*P ≤ .02.

**P < .005.

***P < .0001.

Costs During Index Hospitalization and 30-Day Postdischarge Follow-up

Unadjusted total and ICU costs during index hospitalization, and 30-day postdischarge readmission costs, were higher for all AKI groups than for patients without AKI, and all unadjusted costs were higher for HA-AKI vs CA-AKI (Figure 3, Supplemental Table S4, P < .001 for all). After adjusting for covariates, absolute and relative cost differences remained substantial. Specifically, adjusted mean total costs were $7163 (35%), $3806 (20%) and $23 426 (2.14 times) higher for AKI, CA-AKI, and HA-AKI vs no AKI, but also $19 127 (78%) higher for HA-AKI vs CA-AKI. Among ICU patients, adjusted mean ICU costs were $20 087 (74%), $12 092 (46%), and $37 062 (2.38 times) higher for AKI, CA-AKI, and HA-AKI vs no AKI, but also $25 730 (63%) higher for HA-AKI vs CA-AKI (P < .0001 for all). Among patients with 30-day outpatient visits, adjusted outpatient costs were significantly higher only for HA-AKI vs no AKI ($588, 41%) and HA-AKI vs CA-AKI ($430, 46%) (Figure 3, Supplemental Table S4, P < .001). In contrast, adjusted mean 30-day readmission costs among readmitted patients were similar for all AKI groups vs no AKI.

134672 Figure 3. Mean Costs, Adjusted Mean Difference and Adjusted Cost Ratio by AKI Categories

P < .0001 for all unadjusted comparisons vs no AKI; P < .001 for all unadjusted comparisons of HA-AKI vs CA-AKI. Adjusted models include these covariates: age, sex, race/ethnicity and Charlson Comorbidity Index, hospital characteristics (number of beds, teaching status, region, urban/rural), and admission point of origin, admission type, medical vs surgical (categorized by Medicare Severity Diagnosis Related Group codes), primary payer, ICU use, and chronic kidney disease.

*P ≤ .02.

**P < .005.

***P < .0001.

Finally, sensitivity analyses were conducted with models additionally adjusted for sepsis. All multivariable-adjusted results (aORs, LOS and cost ratios) were minimally affected with this additional adjustment (not shown).

DISCUSSION

To our knowledge, this is the first study to report AKI-related costs among hospitalized COVID-19 patients. In our multicenter study of 208 583 US adults hospitalized with COVID-19 between April 1, 2020, and October 31, 2020, approximately 1 in 3 patients (30%) had AKI; 25% had CA-AKI (at admission), and 5% developed HA-AKI (during hospitalization). Adjusted for potential confounders, all AKI groups (AKI, CA-AKI, and HA-AKI) had higher odds of ICU use and in-hospital mortality, longer total and ICU LOS, and higher total and ICU costs during index hospitalization, and during 30-day postdischarge, had higher odds of dialysis and new dialysis, compared with patients with no AKI. Mean LOS was 13% and 78% longer and mean costs were 20% and 214% higher for CA-AKI and HA-AKI patients vs patients with no AKI. Notably, compared with CA-AKI, patients with HA-AKI had higher ICU use, in-hospital mortality, longer total and ICU LOS, and substantially higher costs during index hospitalization, but similar odds for outcomes during 30 days postdischarge. These results quantify the excess burden of AKI, especially HA-AKI, among COVID-19 patients, some of which might be reduced by early identification and appropriate management of COVID-19 patients at risk of AKI.

Our results for the prevalence of AKI (30% overall, 52.1% in ICU patients), odds of mortality (3.5 times higher for AKI vs no AKI), and mean LOS (11.9 days) are consistent with prior studies that extend past the first few months of the pandemic.11,23 Recent reviews and meta-analyses that include many studies of the early pandemic period reported the following ranges: 28% to 34%11,14,15,40 prevalence of overall AKI, 46% to 77% prevalence of AKI in ICU patients,11,14,40 and 2.55 to 23.09 for OR for mortality.41 Furthermore, in a study of AKI in COVID patients during all of 2020, HR (95% CI) for mortality was 3.8 (3.24-4.45), and mean LOS was 10.4 days.42 Among COVID patients admitted to UK hospitals in 2020, the adjusted OR (95% CI) for in-hospital mortality was 1.91 (1.82-2.01) for biochemically determined AKI (vs no AKI), 2.41 (2.20-2.64) for stage 2 AKI, and 3.50 (3.14-3.91) for stage 3 AKI.43

In our large multicenter study, HA-AKI and CA-AKI occurred in 5% and 25% of patients, and odds of mortality were 2.6 times higher, LOS was 1.6 times longer, and total costs were 1.8 times higher for HA-AKI vs CA-AKI. In 3 prior studies of COVID-19 patients, in-hospital mortality was 1.22 to 2.0 times higher for patients with HA-AKI vs CA-AKI.20–22 In 2 prior studies of COVID-19 patients, mortality was similar for patients with HA-AKI vs CA-AKI, but these studies were small (n = 448 UK patients18 and n = 1170 Mexican patients19) and during the early months of the pandemic when mortality rates were much higher. Length of stay was longer for HA-AKI vs CA-AKI in 2 studies18,19 and similar in 1 study.21 The results from our much larger study are consistent with studies among non-COVID patients, which found higher mortality,16 longer LOS, and higher costs17 for hospitalized patients with HA-AKI vs CA-AKI.

Study limitations include the use of hospital administrative data, which contains less clinical detail than electronic health records. The use of hospital-reported diagnosis procedure codes for diagnoses such as COVID-19 and AKI is well established,34 but ICD-10 codes do not identify AKI stage (ie, KDIGO stage 1, 2, 3). Using ICD codes to identify AKI has high specificity to identify AKI, especially higher-stage AKI, but lower sensitivity, especially for lower-stage AKI.44 Therefore, our study may have included a smaller proportion of stage 1 AKI, resulting in a more severe phenotype and lower prevalence of total AKI than if AKI were based on the changes in serum creatinine. However, this misclassification is likely to be small since the prevalence of AKI in our study is very similar to other recent studies that used KDIGO-defined serum creatinine changes to identify AKI.14,43 Another limitation is that events before (eg, history of dialysis) index hospitalization and 30-day postdischarge outcomes may be underestimated, since patient visits are linked only for visits to the same hospital system. However, we do have all data from the index hospitalizations, and relative differences (odds, LOS, and cost ratios) for 30-day outcomes should be minimally affected, since we expect underestimation to be nondifferential with respect to AKI type during index hospitalization. For example, the incidence of “new” dialysis was less than 1% of patients who survived index hospitalization without dialysis, but AKI, CA-AKI, and HA-AKI all had 2.4 to 2.8 times higher adjusted odds of new dialysis vs patients with no AKI. These results extend the literature showing longer-term adverse renal outcomes of COVID-19-associated AKI.45,46 Finally, a retrospective observational study design cannot prove causality, and results may be affected by unknown confounding. Our study does not have clinical severity scores such as SOFA or APACHE, or medication, but those may be more likely to be a confounder of mortality than cost. Regardless, this study adjusted for many important potential confounders, including age, CKD, and ICU use, and, given the magnitude of adjusted relative differences, it is unlikely that any unmeasured confounders would fully explain the associations between AKI and worse outcomes, particularly higher costs.

Our results have important implications for management of hospitalized COVID-19 patients. In hospitalized patients with and without COVID-19, studies demonstrate improved identification of patients at risk for AKI using risk scores,47,48 or other biomarkers,49 especially urinary biomarkers.24–26,50,51 Several studies, including randomized controlled trials, have shown that urinary biomarker–guided use of the KDIGO bundle resulted in lower incidence of stage 2/3 AKI24–26 and e-alert–guided use of the KDIGO bundle was associated with improved AKI recovery (reversal) within 7 days27 and with reduced LOS28 and costs.30 Still, adherence to best practices remains low in non-COVID patients with or at risk for moderate or severe AKI.26,32,33 Our results suggest that preventing AKI, especially HA-AKI, in COVID-19 patients may reduce adverse clinical outcomes, HRU, and costs, and therefore support implementation of recommended strategies for AKI prevention and management among hospitalized COVID-19 patients.

Author Contributions

R.H.M., J.L.K., N.A.R., L.A.C., J.P.K., P.M., T.R., A.S., and J.T. participated in the design of the study, interpretation of data, and revision of the manuscript. L.C. created the analytic dataset with supervision and review by R.H.M. and N.A.R. R.H.M. performed the statistical analysis and wrote the first draft of the manuscript. R.H.M., J.L.K., N.A.R., L.A.C., J.P.K., P.M., T.R., A.S., and J.T. edited the manuscript and approved of the final version of the manuscript and agree to be accountable for all aspects of the work.

Disclosures

R.H.M., N.A.R., and L.A.C. are full-time employees of Premier, Inc., which received payment from bioMerieux to conduct the study, and have no competing interests with respect to the study. R.H.M., N.A.R., and L.A.C. had access to the study data. J.T., P.M., J.P.K., A.S., and T.R. are full-time employees of bioMerieux, Inc., and P.M. and J.P.K. are inventors on patents assigned to bioMerieux and own shares in bioMerieux. J.L.K. reports consulting fees and research support from Astute-bioMerieux, Fresenius Medical, Mallinckrodt, Novartis, Guard Therapeutics, and the NIH and speakers bureau fees from NXStage Medical. The authors report no other conflicts of interest with this work.

Supplementary Material

Online Supplementary Material
==== Refs
KDIGO Clinical Practice Guideline for Acute Kidney Injury Kidney Int Suppl Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group 2012
2 1 1 138
Use of electronic results reporting to diagnose and monitor AKI in hospitalized patients Clinical Journal of the American Society of Nephrology Selby Nicholas M. Crowley Lisa Fluck Richard J. McIntyre Christopher W. Monaghan John Lawson Nigel Kolhe Nitin V. 23 2 2012
7 4 533 540 1555-9041 10.2215/cjn.08970911 10.2215/cjn.08970911
Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals Clinical Journal of the American Society of Nephrology Zeng Xiaoxi McMahon Gearoid M. Brunelli Steven M. Bates David W. Waikar Sushrut S. 2014
9 1 12 20 1555-9041 10.2215/cjn.02730313 10.2215/cjn.02730313 24178971
Transient and persistent acute kidney injury and the risk of hospital mortality in critically ill patients: results of a multicenter cohort study Critical Care Medicine Perinel Sophie Vincent François Lautrette Alexandre Dellamonica Jean Mariat Christophe Zeni Fabrice Cohen Yves Tardy Bernard Souweine Bertrand Darmon Michael 8 2015
43 8 e269 e275 0090-3493 10.1097/ccm.0000000000001077 10.1097/ccm.0000000000001077 25962084
Evaluation of acute kidney injury (AKI) with RIFLE, AKIN, CK, and KDIGO in critically ill trauma patients European Journal of Trauma and Emergency Surgery Ülger F. Pehlivanlar Küçük M. Küçük A. O. İlkaya N. K. Murat N. Bilgiç B. Abanoz H. 2018
44 4 597 605 1863-9933 10.1007/s00068-017-0820-8 10.1007/s00068-017-0820-8 28717983
Duration of acute kidney injury and mortality in critically ill patients: a retrospective observational study BMC Nephrology Han Seung Seok Kim Sejoong Ahn Shin Young Lee Jeonghwan Kim Dong Ki Chin Ho Jun Chae Dong-Wan Na Ki Young 27 6 2013
14 1 133 1471-2369 10.1186/1471-2369-14-133 10.1186/1471-2369-14-133 23802916
A comparison of different diagnostic criteria of acute kidney injury in critically ill patients Critical Care Luo Xuying Jiang Li Du Bin Wen Ying Wang Meiping Xi Xiuming The Beijing Acute Kidney Injury Trial (BAKIT) workgroup 2014
18 4 R144 1364-8535 10.1186/cc13977 10.1186/cc13977 25005361
Short- and long-term outcomes after non-severe acute kidney injury Clinical and Experimental Nephrology Arias-Cabrales Carlos Rodríguez Eva Bermejo Sheila Sierra Adriana Burballa Carla Barrios Clara Soler María José Pascual Julio 2018
22 1 61 67 1342-1751 10.1007/s10157-017-1420-y 10.1007/s10157-017-1420-y 28551821
Epidemiology and clinical correlates of AKI in Chinese hospitalized adults Clinical Journal of the American Society of Nephrology Xu Xin Nie Sheng Liu Zhangsuo Chen Chunbo Xu Gang Zha Yan Qian Jing Liu Bicheng Han Shuai Xu Anping Xu Xing Hou Fan Fan 31 7 2015
10 9 1510 1518 1555-9041 10.2215/cjn.02140215 10.2215/cjn.02140215 26231194
Review of the literature on the costs associated with acute kidney injury Journal of Pharmacy Practice Dasta Joseph F. Kane-Gill Sandra 6 2019
32 3 292 302 0897-1900 10.1177/0897190019852556 10.1177/0897190019852556 31291842
COVID-19-associated AKI Current Opinion in Critical Care Matsumoto Kenki Prowle John R. 3 10 2022
28 6 630 637 1070-5295 10.1097/mcc.0000000000000988 10.1097/mcc.0000000000000988 36194146
Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis Kidney International Reports Robbins-Juarez Shelief Y. Qian Long King Kristen L. Stevens Jacob S. Husain S. Ali Radhakrishnan Jai Mohan Sumit 8 2020
5 8 1149 1160 2468-0249 10.1016/j.ekir.2020.06.013 10.1016/j.ekir.2020.06.013 32775814
Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis Journal of Investigative Medicine Hansrivijit Panupong Qian Chenchen Boonpheng Boonphiphop Thongprayoon Charat Vallabhajosyula Saraschandra Cheungpasitporn Wisit Ghahramani Nasrollah 10 2020
68 7 1261 1270 1081-5589 10.1136/jim-2020-001407 10.1136/jim-2020-001407 32655013
Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19 Clinical Journal of the American Society of Nephrology Bowe Benjamin Cai Miao Xie Yan Gibson Andrew K. Maddukuri Geetha Al-Aly Ziyad 16 11 2020
16 1 14 25 1555-9041 10.2215/cjn.09610620 10.2215/cjn.09610620 33199414
AKI in hospitalized patients with COVID-19 Journal of the American Society of Nephrology Chan Lili Chaudhary Kumardeep Saha Aparna Chauhan Kinsuk Vaid Akhil Zhao Shan Paranjpe Ishan Somani Sulaiman Richter Felix Miotto Riccardo Lala Anuradha Kia Arash Timsina Prem Li Li Freeman Robert Chen Rong Narula Jagat Just Allan C. Horowitz Carol Fayad Zahi Cordon-Cardo Carlos Schadt Eric Levin Matthew A. Reich David L. Fuster Valentin Murphy Barbara He John C. Charney Alexander W. Böttinger Erwin P. Glicksberg Benjamin S. Coca Steven G. Nadkarni Girish N. on behalf of the Mount Sinai COVID Informatics Center (MSCIC)* 2021
32 1 151 160 1046-6673 10.1681/asn.2020050615 10.1681/asn.2020050615 32883700
Clinical characteristics and outcomes of community-acquired versus hospital-acquired acute kidney injury: a meta-analysis Kidney and Blood Pressure Research Huang Linxi Xue Cheng Kuai Jianke Ruan Mengna Yang Bo Chen Xujiao Zhang Yu Qian Yixin Wu Jun Zhao Xuezhi Mei Changlin Xu Jing Mao Zhiguo 2019
44 5 879 896 1420-4096 10.1159/000502546 10.1159/000502546 31553972
Clinical characteristics and outcomes of patients with severe COVID-19 induced acute kidney injury Journal of Intensive Care Medicine Xu Jingyuan Xie Jianfeng Du Bin Tong Zhaohui Qiu Haibo Bagshaw Sean M. 2021
36 3 319 326 0885-0666 10.1177/0885066620970858 10.1177/0885066620970858 33267722
Community- versus hospital-acquired acute kidney injury in hospitalised COVID-19 patients BMC Nephrology Bell Jack S James Benjamin D Al-Chalabi Saif Sykes Lynne Kalra Philip A Green Darren 23 7 2021
22 1 269 1471-2369 10.1186/s12882-021-02471-2 10.1186/s12882-021-02471-2 34301204
community- and hospital-acquired acute kidney injury in COVID-19: different phenotypes and dismal prognosis Blood Purification Martínez-Rueda Armando J. Álvarez Rigoberto D. Méndez-Pérez R. Angélica Fernández-Camargo Dheni A. Gaytan-Arocha Jorge E. Berman-Parks Nathan Flores-Camargo Areli Comunidad-Bonilla Roque A. Mejia-Vilet Juan M. Arvizu-Hernandez Mauricio Ramirez-Sandoval Juan C. Correa-Rotter Ricardo Vega-Vega Olynka 2021
50 6 931 941 0253-5068 10.1159/000513948 10.1159/000513948 33744901
Clinical characteristics and outcomes of community- and hospital-acquired acute kidney injury with COVID-19 in a US inner city hospital system Cardiorenal Medicine Pelayo Jerald Lo Kevin Bryan Bhargav Ruchika Gul Fahad Peterson Eric DeJoy III Robert Salacup Grace Faith Albano Jeri Gopalakrishnan Akshaya Azmaiparashvili Zurab Patarroyo-Aponte Gabriel Rangaswami Janani 2020
10 4 223 231 1664-3828 10.1159/000509182 10.1159/000509182 32554965
Mortality and evolution between community and hospital-acquired COVID-AKI PLoS One Chávez-Íñiguez Jonathan S. Cano-Cervantes José H. Maggiani-Aguilera Pablo Lavelle-Góngora Natashia Marcial-Meza Josué Camacho-Murillo Estefanía P. Moreno-González Cynthia Tanaka-Gutiérrez Jarumi A. Villa Zaragoza Ana P. Rincón-Souza Karla E. Muñoz-López Sandra Montoya-Montoya Olivia Navarro-Blackaller Guillermo Sánchez-Cedillo Aczel Morales-Buenrostro Luis E. García-García Guillermo 4 11 2021
16 11 e0257619 1932-6203 10.1371/journal.pone.0257619 10.1371/journal.pone.0257619 34735451
Longitudinal clinical profiles of hospital vs community-acquired acute kidney injury in COVID-19 Frontiers in Medicine Lu Justin Y. Babatsikos Ioannis Fisher Molly C. Hou Wei Duong Tim Q. 28 5 2021
8 647023 2296-858X 10.3389/fmed.2021.647023 10.3389/fmed.2021.647023 34124089
COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup Nature Reviews Nephrology Nadim Mitra K. Forni Lui G. Mehta Ravindra L. Connor Michael J. Jr Liu Kathleen D. Ostermann Marlies Rimmelé Thomas Zarbock Alexander Bell Samira Bihorac Azra Cantaluppi Vincenzo Hoste Eric Husain-Syed Faeq Germain Michael J. Goldstein Stuart L. Gupta Shruti Joannidis Michael Kashani Kianoush Koyner Jay L. Legrand Matthieu Lumlertgul Nuttha Mohan Sumit Pannu Neesh Peng Zhiyong Perez-Fernandez Xose L. Pickkers Peter Prowle John Reis Thiago Srisawat Nattachai Tolwani Ashita Vijayan Anitha Villa Gianluca Yang Li Ronco Claudio Kellum John A. 15 10 2020
16 12 747 764 1759-5061 10.1038/s41581-020-00356-5 10.1038/s41581-020-00356-5 33060844
Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial Intensive Care Medicine Meersch Melanie Schmidt Christoph Hoffmeier Andreas Van Aken Hugo Wempe Carola Gerss Joachim Zarbock Alexander 21 1 2017
43 11 1551 1561 0342-4642 10.1007/s00134-016-4670-3 10.1007/s00134-016-4670-3 28110412
Using urinary biomarkers to reduce acute kidney injury following cardiac surgery J Thorac Cardiovasc Surg Engelman D.T. Crisafi C. Germain M.. 2020
160 5 1235 1246e2 10.1016/j.jtcvs2019.10.034 10.1016/j.jtcvs2019.10.034 31757451
Prevention of cardiac surgery-associated acute kidney injury by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: the PrevAKI-Multicenter Randomized Controlled Trial Anesthesia & Analgesia Zarbock Alexander Küllmar Mira Ostermann Marlies Lucchese Gianluca Baig Kamran Cennamo Armando Rajani Ronak McCorkell Stuart Arndt Christian Wulf Hinnerk Irqsusi Marc Monaco Fabrizio Di Prima Ambra Licia García Alvarez Mercedes Italiano Stefano Miralles Bagan Jordi Kunst Gudrun Nair Shrijit L’Acqua Camilla Hoste Eric Vandenberghe Wim Honore Patrick M. Kellum John A. Forni Lui G. Grieshaber Philippe Massoth Christina Weiss Raphael Gerss Joachim Wempe Carola Meersch Melanie 8 5 2021
133 2 292 302 0003-2999 10.1213/ane.0000000000005458 10.1213/ane.0000000000005458 33684086
Biomarker-guided intervention to prevent acute kidney injury after major surgery: the Prospective Randomized BigpAK Study Annals of Surgery Göcze Ivan Jauch Dominik Götz Markus Kennedy Pascal Jung Bettina Zeman Florian Gnewuch Carsten Graf Bernhard M. Gnann Wolfgang Banas Bernhard Bein Thomas Schlitt Hans J. Bergler Tobias 6 2018
267 6 1013 1020 0003-4932 10.1097/sla.0000000000002485 10.1097/sla.0000000000002485 28857811
An organizational-level program of intervention for AKI: a pragmatic stepped wedge cluster randomized trial Journal of the American Society of Nephrology Selby Nicholas M. Casula Anna Lamming Laura Stoves John Samarasinghe Yohan Lewington Andrew J. Roberts Russell Shah Nikunj Johnson Melanie Jackson Natalie Jones Carol Lenguerrand Erik McDonach Eileen Fluck Richard J. Mohammed Mohammed A. Caskey Fergus J. 21 2 2019
30 3 505 515 1046-6673 10.1681/asn.2018090886 10.1681/asn.2018090886 31058607
A simple care bundle for use in acute kidney injury: a propensity score-matched cohort study Nephrology Dialysis Transplantation Kolhe Nitin V. Reilly Timothy Leung Janson Fluck Richard J. Swinscoe Kirsty E. Selby Nicholas M. Taal Maarten W. 4 5 2016
31 11 1846 1854 0931-0509 10.1093/ndt/gfw087 10.1093/ndt/gfw087
Randomized controlled trial evidence of cost-effectiveness of a multifaceted AKI intervention approach Kidney International Reports Selby Nicholas M. Korrodi-Gregório Luís Casula Anna Kolhe Nitin V. Arbonés Daniel Ribes Bukieda Katelyn D. Sahu Deepak Rao Chris Basadonna Giacomo 3 2021
6 3 636 644 2468-0249 10.1016/j.ekir.2020.12.004 10.1016/j.ekir.2020.12.004 33732978
A prospective micro-costing pilot study of the health economic costs of acute kidney injury Kidney International Reports Mistry Hema Abdelaziz Tarek Samy Thomas Mark 11 2018
3 6 1285 1293 2468-0249 10.1016/j.ekir.2018.06.006 10.1016/j.ekir.2018.06.006 30450455
Variation in best practice measures in patients with severe hospital-acquired acute kidney injury: a multicenter study Am J Kidney Dis Moledina D.G. Belliveau O. Yamamoto Y.. 2021
77 4 547 549 10.1053/j.ajkd.2020.08.013 10.1053/j.ajkd.2020.08.013 33075389
A multinational observational study exploring adherence with the kidney disease: improving global outcomes recommendations for prevention of acute kidney injury after cardiac surgery Anesthesia & Analgesia Küllmar Mira Weiß Raphael Ostermann Marlies Campos Sara Grau Novellas Neus Thomson Gary Haffner Michael Arndt Christian Wulf Hinnerk Irqsusi Marc Monaco Fabrizio Di Prima Ambra Licia García-Alvarez Mercedes Italiano Stefano Felipe Correoso Mar Kunst Gudrun Nair Shrijit L’Acqua Camilla Hoste Eric Vandenberghe Wim Honore Patrick M. Kellum John A. Forni Lui Grieshaber Philippe Wempe Carola Meersch Melanie Zarbock Alexander 4 2020
130 4 910 916 0003-2999 10.1213/ane.0000000000004642 10.1213/ane.0000000000004642 31922998
Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations JAMA Kadri Sameer S. Gundrum Jake Warner Sarah Cao Zhun Babiker Ahmed Klompas Michael Rosenthal Ning 22 12 2020
324 24 2553 2554 0098-7484 10.1001/jama.2020.20323 10.1001/jama.2020.20323 33351033
Aprotinin during coronary-artery bypass grafting and risk of death New England Journal of Medicine Schneeweiss Sebastian Seeger John D. Landon Joan Walker Alexander M. 21 2 2008
358 8 771 783 0028-4793 10.1056/nejmoa0707571 10.1056/nejmoa0707571
Association of robotic-assisted vs laparoscopic radical nephrectomy with perioperative outcomes and health care costs, 2003 to 2015 JAMA Jeong In Gab Khandwala Yash S. Kim Jae Heon Han Deok Hyun Li Shufeng Wang Ye Chang Steven L. Chung Benjamin I. 24 10 2017
318 16 1561 1568 0098-7484 10.1001/jama.2017.14586 10.1001/jama.2017.14586 29067427
Is COVID-19 less deadly now? Trends of in-hospital mortality among hospitalized COVID-19 patients in the United States Clinical Infectious Diseases Moon Rena C Mackey Rachel H Cao Zhun Emont Seth Schott Laura L Gayle Julie A Lipkin Craig Rosenthal Ning A 17 9 2021
74 12 2238 2242 1058-4838 10.1093/cid/ciab830 10.1093/cid/ciab830 34534276
Review of statistical methods for analysing healthcare resources and costs Health Economics Mihaylova Borislava Briggs Andrew O'Hagan Anthony Thompson Simon G. 2011
20 8 897 916 1057-9230 10.1002/hec.1653 10.1002/hec.1653 20799344
Estimating marginal and incremental effects on health outcomes using flexible link and variance function models Biostatistics Basu A. Rathouz P. J. 2005
6 1 93 109 1465-4644 10.1093/biostatistics/kxh020 10.1093/biostatistics/kxh020 15618530
The prevalence of acute kidney injury in patients hospitalized with COVID-19 infection: a systematic review and meta-analysis Kidney Medicine Silver Samuel A. Beaubien-Souligny William Shah Prakesh S. Harel Shai Blum Daniel Kishibe Teruko Meraz-Munoz Alejandro Wald Ron Harel Ziv 1 2021
3 1 83 98.e1 2590-0595 10.1016/j.xkme.2020.11.008 10.1016/j.xkme.2020.11.008 33319190
Incidence, risk factors and outcomes of acute kidney injury among COVID-19 patients: a systematic review of systematic reviews Frontiers in Medicine Mallhi Tauqeer Hussain Khan Yusra Habib Alzarea Abdulaziz Ibrahim Khan Faiz Ullah Alotaibi Nasser Hadal Alanazi Abdullah Salah Butt Muhammad Hammad Alatawi Ahmed D. Salman Muhammad Alzarea Sami I. Almalki Ziyad Saeed Alghazi Mansoor A. Algarni Majed Ahmed 4 11 2022
9 973030 2296-858X 10.3389/fmed.2022.973030 10.3389/fmed.2022.973030 36405588
Changes of acute kidney injury epidemiology during the COVID-19 pandemic: a retrospective cohort study Journal of Clinical Medicine Esposito Pasquale Russo Elisa Picciotto Daniela Cappadona Francesca Battaglia Yuri Traverso Giovanni Battista Viazzi Francesca 10 6 2022
11 12 3349 2077-0383 10.3390/jcm11123349 10.3390/jcm11123349 35743418
Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study Nephrology Dialysis Transplantation Sullivan Michael K Lees Jennifer S Drake Thomas M Docherty Annemarie B Oates Georgia Hardwick Hayley E Russell Clark D Merson Laura Dunning Jake Nguyen-Van-Tam Jonathan S Openshaw Peter Harrison Ewen M Baillie J Kenneth Baillie J Kenneth Semple Malcolm G Openshaw Peter J M Carson Gail Alex Beatrice Bach Benjamin Barclay Wendy S Bogaert Debby Chand Meera Cooke Graham S Docherty Annemarie B Dunning Jake da Silva Filipe Ana Fletcher Tom Green Christoper A Harrison Ewen M Hiscox Julian A Ho Antonia Ying Wai Horby Peter W Ijaz Samreen Khoo Saye Klenerman Paul Law Andrew Lim Wei Shen Mentzer Alexander J Merson Laura Meynert Alison M Noursadeghi Mahdad Moore Shona C Palmarini Massimo Paxton William A Pollakis Georgios Price Nicholas Rambaut Andrew Robertson David L Russell Clark D Sancho-Shimizu Vanessa Scott Janet T de Silva Thushan Sigfrid Louise Solomon Tom Sriskandan Shiranee Stuart David Summers Charlotte Tedder Richard S Thomson Emma C Thompson A A Roger Thwaites Ryan S Turtle Lance C W Zambon Maria Hardwick Hayley Donohue Chloe Lyons Ruth Griffiths Fiona Oosthuyzen Wilna Norman Lisa Pius Riinu Drake Thomas M Fairfield Cameron J Knight Stephen R Mclean Kenneth A Murphy Derek Shaw Catherine A Dalton Jo Girvan Michelle Saviciute Egle Roberts Stephanie Harrison Janet Marsh Laura Connor Marie Halpin Sophie Jackson Clare Gamble Carrol Leeming Gary Law Andrew Wham Murray Clohisey Sara Hendry Ross Scott-Brown James Greenhalf William Shaw Victoria McDonald Sara Keating Seán Ahmed Katie A Armstrong Jane A Ashworth Milton Asiimwe Innocent G Bakshi Siddharth Barlow Samantha L Booth Laura Brennan Benjamin Bullock Katie Catterall Benjamin W A Clark Jordan J Clarke Emily A Cole Sarah Cooper Louise Cox Helen Davis Christopher Dincarslan Oslem Dunn Chris Dyer Philip Elliott Angela Evans Anthony Finch Lorna Fisher Lewis W S Foster Terry Garcia-Dorival Isabel Greenhalf William Gunning Philip Hartley Catherine Jensen Rebecca L Jones Christopher B Jones Trevor R Khandaker Shadia King Katharine Kiy Robyn T Koukorava Chrysa Lake Annette Lant Suzannah Latawiec Diane Lavelle-Langham Lara Lefteri Daniella Lett Lauren Livoti Lucia A Mancini Maria McDonald Sarah McEvoy Laurence McLauchlan John Metelmann Soeren Miah Nahida S Middleton Joanna Mitchell Joyce Moore Shona C Murphy Ellen G Penrice-Randal Rebekah Pilgrim Jack Prince Tessa Reynolds Will Ridley P Matthew Sales Debby Shaw Victoria E Shears Rebecca K Small Benjamin Subramaniam Krishanthi S Szemiel Agnieska Taggart Aislynn Tanianis-Hughes Jolanta Thomas Jordan Trochu Erwan van Tonder Libby Wilcock Eve Zhang J Eunice Flaherty Lisa Maziere Nicole Cass Emily Carracedo Alejandra Doce Carlucci Nicola Holmes Anthony Massey Hannah Murphy Lee Wrobel Nicola McCafferty Sarah Morrice Kirstie MacLean Alan Adeniji Kayode Agranoff Daniel Agwuh Ken Ail Dhiraj Aldera Erin L Alegria Ana Angus Brian Ashish Abdul Atkinson Dougal Bari Shahedal Barlow Gavin Barnass Stella Barrett Nicholas Bassford Christopher Basude Sneha Baxter David Beadsworth Michael Bernatoniene Jolanta Berridge John Best Nicola Bothma Pieter Chadwick David Brittain-Long Robin Bulteel Naomi Burden Tom Burtenshaw Andrew Caruth Vikki Chadwick David Chambler Duncan Chee Nigel Child Jenny Chukkambotla Srikanth Clark Tom Collini Paul Cosgrove Catherine Cupitt Jason Cutino-Moguel Maria-Teresa Dark Paul Dawson Chris Dervisevic Samir Donnison Phil Douthwaite Sam DuRand Ingrid Dushianthan Ahilanadan Dyer Tristan Evans Cariad Eziefula Chi Fegan Chrisopher Finn Adam Fullerton Duncan Garg Sanjeev Garg Sanjeev Garg Atul Gkrania-Klotsas Effrossyni Godden Jo Goldsmith Arthur Graham Clive Hardy Elaine Hartshorn Stuart Harvey Daniel Havalda Peter Hawcutt Daniel B Hobrok Maria Hodgson Luke Hormis Anil Jacobs Michael Jain Susan Jennings Paul Kaliappan Agilan Kasipandian Vidya Kegg Stephen Kelsey Michael Kendall Jason Kerrison Caroline Kerslake Ian Koch Oliver Koduri Gouri Koshy George Laha Shondipon Laird Steven Larkin Susan Leiner Tamas Lillie Patrick Limb James Linnett Vanessa Little Jeff Lyttle Mark MacMahon Michael MacNaughton Emily Mankregod Ravish Masson Huw Matovu Elijah McCullough Katherine McEwen Ruth Meda Manjula Mills Gary Minton Jane Mirfenderesky Mariyam Mohandas Kavya Mok Quen Moon James Moore Elinoor Morgan Patrick Morris Craig Mortimore Katherine Moses Samuel Mpenge Mbiye Mulla Rohinton Murphy Michael Nagel Megan Nagarajan Thapas Nelson Mark O'Shea Matthew K Otahal Igor Ostermann Marlies Pais Mark Panchatsharam Selva Papakonstantinou Danai Paraiso Hassan Patel Brij Pattison Natalie Pepperell Justin Peters Mark Phull Mandeep Pintus Stefania Pooni Jagtur Singh Post Frank Price David Prout Rachel Rae Nikolas Reschreiter Henrik Reynolds Tim Richardson Neil Roberts Mark Roberts Devender Rose Alistair Rousseau Guy Ryan Brendan Saluja Taranprit Shah Aarti Shanmuga Prad Sharma Anil Shawcross Anna Sizer Jeremy Shankar-Hari Manu Smith Richard Snelson Catherine Spittle Nick Staines Nikki Stambach Tom Stewart Richard Subudhi Pradeep Szakmany Tamas Tatham Kate Thomas Jo Thompson Chris Thompson Robert Tridente Ascanio Tupper-Carey Darell Twagira Mary Ustianowski Andrew Vallotton Nick Vincent-Smith Lisa Visuvanathan Shico Vuylsteke Alan Waddy Sam Wake Rachel Walden Andrew Welters Ingeborg Whitehouse Tony Whittaker Paul Whittington Ashley Papineni Padmasayee Wijesinghe Meme Williams Martin Wilson Lawrence Cole Sarah Winchester Stephen Wiselka Martin Wolverson Adam Wooton Daniel G Workman Andrew Yates Bryan Young Peter Semple Malcolm G Ho Antonia Mark Patrick B ISARIC4C Investigators 2022
37 2 271 284 0931-0509 10.1093/ndt/gfab303 10.1093/ndt/gfab303 34661677
Performance and limitations of administrative data in the identification of AKI Clinical Journal of the American Society of Nephrology Grams Morgan E. Waikar Sushrut S. MacMahon Blaithin Whelton Seamus Ballew Shoshana H. Coresh Josef 23 1 2014
9 4 682 689 1555-9041 10.2215/cjn.07650713 10.2215/cjn.07650713 24458075
Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19 JAMA Network Open Nugent James Aklilu Abinet Yamamoto Yu Simonov Michael Li Fan Biswas Aditya Ghazi Lama Greenberg Jason H. Mansour Sherry G. Moledina Dennis G. Wilson F. Perry 10 3 2021
4 3 e211095 2574-3805 10.1001/jamanetworkopen.2021.1095 10.1001/jamanetworkopen.2021.1095 33688965
Kidney outcomes in long COVID Journal of the American Society of Nephrology Bowe Benjamin Xie Yan Xu Evan Al-Aly Ziyad 1 9 2021
32 11 2851 2862 1046-6673 10.1681/asn.2021060734 10.1681/asn.2021060734 34470828
A validation study of UCSD-Mayo risk score in predicting hospital-acquired acute kidney injury in COVID-19 patients Renal Failure Fang Zhengying Gao Chenni Cai Yikai Lu Lin Yu Haijin Hussain Hafiz Muhammad Jafar Chen Zijin Li Chuanlei Wei Wenjie Huang Yuhan Li Xiang Yu Shuwen Ji Yinhong Weng Qinjie Ouyang Yan Hu Xiaofan Tong Jun Liu Jian Liu Mingyu Xu Xiaoman Zha Yixin Ye Zhiyin Jiang Tingting Jia Jieshuang Liu Jialin Bi Yufang Chen Nan Hu Weiguo Wang Huiming Liu Jun Xie Jingyuan 1 1 2021
43 1 1115 1123 0886-022X 10.1080/0886022x.2021.1948429 10.1080/0886022x.2021.1948429 34233570
A risk score based on procalcitonin for predicting acute kidney injury in COVID-19 patients Journal of Clinical Laboratory Analysis Wang Ruo Ran He Min Kang Yan 25 5 2021
35 6 e23805 0887-8013 10.1002/jcla.23805 10.1002/jcla.23805 34032326
Longitudinal prediction of hospital-acquired acute kidney injury in COVID-19: a two-center study Infection Lu Justin Y. Hou Wei Duong Tim Q. 2022
50 1 109 119 0300-8126 10.1007/s15010-021-01646-1 10.1007/s15010-021-01646-1 34176087
Prognostic significance of urinary biomarkers in patients hospitalized with COVID-19 American Journal of Kidney Diseases Menez Steven Moledina Dennis G. Thiessen-Philbrook Heather Wilson F. Perry Obeid Wassim Simonov Michael Yamamoto Yu Corona-Villalobos Celia P. Chang Crystal Garibaldi Brian T. Clarke William Farhadian Shelli Dela Cruz Charles Coca Steven G. Parikh Chirag R. Ko Albert Iwasaki Akiko Farhadian Shelli Nelson Allison Casanovas-Massana Arnau White Elizabeth B. Schulz Wade Coppi Andreas Young Patrick Nunez Angela Shepard Denise Matos Irene Strong Yvette Anastasio Kelly Brower Kristina Kuang Maxine Chiorazzi Michael Bermejo Santos Vijayakumar Pavithra Geng Bertie Fournier John Minasyan Maksym Muenker M. Catherine Moore Adam J. Nadkarni Girish 2 2022
79 2 257 267.e1 0272-6386 10.1053/j.ajkd.2021.09.008 10.1053/j.ajkd.2021.09.008 34710516
Role of urinary kidney stress biomarkers for early recognition of subclinical acute kidney injury in critically ill COVID-19 patients Biomolecules Casas-Aparicio Gustavo Alvarado-de la Barrera Claudia Escamilla-Illescas David León-Rodríguez Isabel Del Río-Estrada Perla Mariana Calderón-Dávila Natalia González-Navarro Mauricio Olmedo-Ocampo Rossana Castillejos-López Manuel Figueroa-Hernández Liliana Peralta-Prado Amy Luna-Villalobos Yara Piten-Isidro Elvira Fernández-Campos Paola Ávila-Ríos Santiago 8 2 2022
12 2 275 2218-273X 10.3390/biom12020275 10.3390/biom12020275 35204776
